SCHEDULE: Hilve Holdings, Stiskin Disclose 5.7% Stake in electroCore

Hilve Holdings Ltd and Mikhail Stiskin have disclosed a beneficial ownership of 5.7% in electroCore, Inc., totaling 432,000 shares of common stock.

Summary

• Hilve Holdings Ltd and Mikhail Stiskin (collectively, the "Reporting Persons") have filed a Schedule 13G with the SEC.
• They beneficially own 432,000 shares of electroCore, Inc.'s Common Stock, par value $0.001 per share.
• This ownership represents 5.7% of the outstanding shares of Common Stock.
• The percentage is calculated based on 7,583,445 shares of Common Stock outstanding as of August 5, 2025, as reported in electroCore's Form 10-Q filed on August 6, 2025.
• Mikhail Stiskin, as the sole shareholder of Hilve Holdings Ltd, is deemed to be the beneficial owner of the same 432,000 shares.
• The shares were not acquired and are not held for the purpose of changing or influencing the control of electroCore, Inc.

Sentiment

Score: 6

Explanation: The filing indicates a new significant investor has taken a stake in the company, which is generally a positive signal of confidence, though it provides no operational or financial updates.

Positives

• A new significant investor, Hilve Holdings Ltd, and an individual investor, Mikhail Stiskin, have taken a 5.7% stake in electroCore, Inc., which can be interpreted as a vote of confidence in the company's future prospects.

Future Outlook

No forward-looking statements or guidance are provided in this beneficial ownership disclosure.

Industry Context

The disclosure of a significant stake by new investors in electroCore, a company operating in the medical device and neuromodulation sector, could signal growing interest in the therapeutic potential of its gammaCore non-invasive vagus nerve stimulation (nVNS) technology. This sector is characterized by innovation in treating neurological and inflammatory conditions, attracting investors seeking exposure to emerging healthcare technologies.

Stakeholder Impact

• Shareholders: The disclosure of a new significant investor may be viewed positively, potentially increasing confidence and demand for the stock.
• Company Management: Awareness of a new 5.7% shareholder may influence future strategic decisions or engagement.

Key Dates

Recommendation

The filing indicates a new significant investor, Hilve Holdings Ltd and Mikhail Stiskin, has acquired a 5.7% stake in electroCore, Inc. While this suggests confidence from the reporting persons, the Schedule 13G itself does not provide operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It is a disclosure of ownership, which is generally a neutral to slightly positive event, suggesting existing investors should 'hold' and monitor for further developments or operational updates.

Keywords

electroCore Inc, Common Stock, Schedule 13G, Beneficial Ownership, Hilve Holdings Ltd, Mikhail Stiskin, Medical Devices, Neuromodulation